ARCHIVES

Phase III Trial Would Give Clearer Picture of C225 Role

This article is from The Cancer Letter archive.

Vol. 28 No. | March 8, 2002

Download PDF Visit The Full Archive

Related Articles

Revive Comprehensive Program, But Don’t Tie It to Grant Review, Center Executive Agrees

July 29, 1988

DCCR Receives 59 Community Hospital Oncology Program Proposals, Only here From Rural Areas

September 21, 1979

Tamoxifen Trial Enrolls 19% Of Women Needed, Fisher Reports To NCAB

October 16, 1992

In Brief: Marks’ Appointment As President, Chief Executive Officer Of Memorial Sloan-Kettering, Official

June 27, 1980

DCT Board Restores Funding to Rosenberg’s Lymphocyte Projects

June 17, 1994

Two Trials Presented at ASCO Demonstrate Drop in Death Risk, Increased Survival

June 24, 2011